ArticleOncology letters2026
DNA hypermethylation of nonspecific cytotoxic cell receptor protein 1 and poor prognosis of pancreatic cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) is a highly fatal malignancy and one of the leading causes of cancer-related deaths globally. Pancreatitis and inflammation-induced epigenetic changes, such as DNA methylation, have been reported to be involved in carcinogenesis and progression of PC. The present study examined the precise expression and DNA methylation status of nonspecific cytotoxic cell receptor protein 1 (NCCRP1), identified as a methylation target gene in esophageal cancers, in paired adjacent normal pancreas and PC tissues. NCCRP1 expression was immunohistochemically analyzed using formalin-fixed, paraffin-embedded sections of 73 patients with PC who underwent surgery. The DNA methylation status was analyzed in 52 paired adjacent normal and PC tissues using pyrosequencing. In normal pancreatic tissues, NCCRP1 expression was restricted to acinar cells and absent in ductal and islet cells. Most PCs (64/73) showed a loss of NCCRP1 expression, whereas NCCRP1 expression was observed in 9 cases. Among the NCCRP1-positive cases, 8 (89%) were classified as anaplastic carcinoma, an undifferentiated subtype of PC. When human PC cell lines were treated with 5-aza-2'-deoxycytidine, a DNA-methyltransferase inhibitor, NCCRP1 transcription was induced. Pyrosequencing analysis revealed that the promoter regions of NCCRP1 were highly DNA methylated in PC tissues compared with paired adjacent normal tissues. Furthermore, PC cases with DNA hypermethylated (>18.88%) NCCRP1 exhibited significantly poorer survival than those with relatively low levels of NCCRP1 methylation (P=0.0164). The data collectively suggested that NCCRP1 expression was frequently lost in PC, likely due to promoter hypermethylation, resulting in poor prognosis. This indicates the potential of NCCRP1 as a diagnostic and prognostic biomarker and a therapeutic target for patients with PC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.